An introduction to antiepileptic drugs

被引:112
作者
Perucca, E
机构
[1] Univ Pavia, Dept Internal Med & Therapeut, Clin Pharmacol Unit, I-27100 Pavia, Italy
[2] IRCCS C Mondino Fdn, Inst Neurol, Pavia, Italy
关键词
antiepileptic drugs; epilepsy; drug therapy; clinical pharmacology; review;
D O I
10.1111/j.1528-1167.2005.463007.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In recent years, the number of commercially available antiepileptic drugs (AEDs) has increased steadily. Although this may complicate management choices, it also offers welcome new options to individualize treatment more effectively. Because each of the available AEDs differs from others in many clinically relevant properties, opportunities to tailor drug treatment to the characteristics of the individual patient have never been greater. Properties that are especially important in drug selection in patients with epilepsy include spectrum of efficacy in different seizure types, adverse effects profile, pharmacokinetic properties, susceptibility to cause or be a target of clinically important drug-drug interactions, ease of use, and cost. Other factors that need to be considered in tailoring drug choice include availability of user-friendly pediatric formulations, and potentially favorable effects on co-morbid conditions. In fact, a number of AEDs are efficacious and widely prescribed in additional indications, particularly psychiatric disorders, migraine prophylaxis, and neuropathic pain. Recently, advances have been made in understanding the mechanisms of actions of AEDs at the molecular level. While a fully mechanistic approach to the clinical use of these agents is not yet feasible, knowledge of mechanisms of action offers useful clues in predicting their efficacy profile and spectrum of potential adverse effects.
引用
收藏
页码:31 / 37
页数:7
相关论文
共 53 条
[1]  
BATTINO D, 2000, MEYLERS SIDE EFFECTS, P164
[2]   THE MANAGEMENT OF EPILEPSY IN THE 1990S - ACQUISITIONS, UNCERTAINTIES AND PRIORITIES FOR FUTURE-RESEARCH [J].
BEGHI, E ;
PERUCCA, E .
DRUGS, 1995, 49 (05) :680-694
[3]   Carbamazepine toxicity with lamotrigine: Pharmacokinetic or pharmacodynamic interaction? [J].
Besag, FMC ;
Berry, DJ ;
Pool, F ;
Newbery, JE ;
Subel, B .
EPILEPSIA, 1998, 39 (02) :183-187
[4]   Approaches to reducing the incidence of lamotrigine-induced rash [J].
Besag, FMC .
CNS DRUGS, 2000, 13 (01) :21-33
[5]   Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy [J].
Brodie, MJ ;
Overstall, PW ;
Giorgi, L .
EPILEPSY RESEARCH, 1999, 37 (01) :81-87
[6]   Lamotrigine substitution study: Evidence for synergism with sodium valproate? [J].
Brodie, MJ ;
Yuen, AWC .
EPILEPSY RESEARCH, 1997, 26 (03) :423-432
[7]   Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis [J].
Chiron, C ;
Dumas, C ;
Jambaque, I ;
Mumford, J ;
Dulac, O .
EPILEPSY RESEARCH, 1997, 26 (02) :389-395
[8]   THE ROLE OF THERAPEUTIC DRUG-MONITORING IN IMPROVING THE COST-EFFECTIVENESS OF ANTICONVULSANT THERAPY [J].
EADIE, MJ .
CLINICAL PHARMACOKINETICS, 1995, 29 (01) :29-35
[9]  
Evins AE, 2003, J CLIN PSYCHIAT, V64, P9
[10]   Inhibition of neuronal Ca2+ influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices [J].
Fink, K ;
Meder, W ;
Dooley, DJ ;
Göthert, M .
BRITISH JOURNAL OF PHARMACOLOGY, 2000, 130 (04) :900-906